<DOC>
	<DOC>NCT02586909</DOC>
	<brief_summary>This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind study).</brief_summary>
	<brief_title>12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension</brief_title>
	<detailed_description>This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001. Various background therapies, including acetylcholinesterase inhibitors and memantine, will be allowed.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Completed last ontreatment visit of the leadin study RVT1013001 Any clinically relevant concomitant disease, which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>RVT-101</keyword>
	<keyword>donepezil</keyword>
</DOC>